Suggestions for treatment Treatment Options1 Acne Severity Mild to moderate
2nd line options
• Topical retinoid + BP2 • Topical antibiotic3,4 + BP • Topical antibiotic3,4 +
Moderate to severe 3rd line options
*Severe presentations (e.g. nodulocystic acne or acne
fulminans) may require initiation of therapy with 3rd line
Combined oral contraceptives Spironolactone or low dose6,8 oral isotretinoin
1 – Wait 8 to 12 weeks before changing from one therapy to another.
2 – It is reasonable to consider topical retinoids with BP as second line therapy, especially if the goal is to
minimize antibiotic use. Evidence for the effect of benzoyl peroxide plus a topical retinoid versus either agent alone is inconsistent. (There is consistent evidence that topical clindamycin + BP is superior to BP alone).
3 – Do not switch from one topical antibiotic to another. Change to oral agent if antibiotic treatment desired
4 – Long term therapy with topical or oral antibiotics is not recommended due to concerns of developing
resistance. • Topical or oral antibiotics are used only to gain a measure of control over inflammatory lesions and
should be stopped when there is no further inflammation.
• Response to topical or oral antibiotics usually occurs within 3 months. Once patients respond (no
further inflammation) consider “stepping down” to benzoyl peroxide or a topical retinoid to maintain response.
5 – The addition of benzoyl peroxide may address resistance concerns and may lead to better outcomes.
Separate the application of benzoyl peroxide products from other topical products by applying one in the morning and the other in the evening.
6 – When starting oral isotretinoin discontinue other therapies.
7 – 1st line in women also wanting birth control or add on treatment to 1st and 2nd line therapies in women
with no contraindications. Some suggest use ahead of oral antibiotics.
8 – Expert opinion suggests 20 mg oral isotretinoin daily X 6 months as treatment option for adult onset acne.
Wholesale costs of acne therapies, not including dispensing fee - June 2008 Preparations Concentration Pack size Cost / g or ml Benzoyl Peroxide Water based gel Alcohol based gel Acetone based gel Retinoids Cream Solution
1 - costs of different concentrations are the same for each preparation
Combination BP/topical antibiotic preparations Clindoxyl (BP 5%/Clin 1%) is given a 4 month expiry date after dispensing. Stored at room temperature by the patient. BenzaClin (BP 5%/Clin 1%) is given a 3 month expiry date after dispensing. Stored at room temperature by the patient.
Benzamymcin (BP 5%/Ery 3%) is given a 3 month expiry date after dispensing.
Requires refrigeration by the patient. Topical antibiotics Preparations Concentration Pack size Cost / g or ml Clindamycin Erythromycin Combination products BP + clindamycin BP + erythro Tretinoin + erythro Oral antibiotics
Strength Cost / unit 90 day cost Tetracyclines Erythromycins Combined oral contraceptives Trade name Contents Cost / month Oral isotretinoin Cost: 5 mos for Trade name 60 kg person
Then alternate 40 mg on day 1 and 80 mg on day 2 for 4 months 40 mg once daily for 1 month
Then 60 mg once daily (40 mg plus 2 x 10 mg) for 4 months 40 mg once daily for 1 month
Then alternate 40 mg on day 1 and 80 mg on day 2 for 4 months 40 mg once daily for 1 month
Then 60 mg once daily (40 mg plus 2 x 10 mg) for 4 months
Dalhousie Academic Detailing Service. Source McKesson Canada Maritimes, Wholesale Distributor. June 2008
integrerad BÖRJAN - Mark 16:15 Gå ut i hela världen och predika de goda nyheterna för alla människor VI ÄR HÄR! SLUTET- Upp 7:9 en stor skara som ingen kunde räkna, alla folkslag och stammar och William Carey 1761-1831 länder och språk Pioneer Tentmaker Missionary to India 97% av onådda bor i länder där traditionell misssio
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) December 2000 Additional copies are available from: Office of Training and Communications Division of Communications Management (Internet) http://www.fda.gov/cder/guidance/index.htm Office of Communication